Inve
IN ⇄ US

SYMBIOTEC share price & results

SYMBIOTEC· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Company research is public. Sign in to keep your own companies, notes and cases.

Inve AI Signals on SYMBIOTEC
Direct bridge to live research & tools watching SYMBIOTEC
Guidance Hit Rate
Guidance Ledger Check management promises →
Segment Shift
Sector & Mix Compare sector growth & peers →
Reverse DCF
Implied Growth Test priced-in growth in DCF tool →
Concall & Tone
Q1 FY27 analysed Read claims, qualifiers & Q&A →

Price & Snapshot

₹1,271.5 +3.11% · +₹38.3

Last close 5 Nov 2026 · NSE · INR · Source: Inve

Performance +15.8% YTD

₹1.0k₹1.1k₹1.2k₹1.3kSeptOctNovQ1 FY27 — 22 Sept 2026

YTD: ₹1,097.7 on 1 Sept 2026 → ₹1,271.5. High ₹1,279.5 (16 Oct 2026), low ₹1,003.35 (25 Sept 2026).

Previous close
₹1,233.2
Market cap
₹8.2k Cr
52-week range
₹1,003.35 – ₹1,279.5
Price to earnings (FY ending Mar 2026)
71.04×
Return on equity (FY ending Mar 2026)
11.70%

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue7.0 ₹ crore−96.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.0 %−8.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit14.0 ₹ crore−53.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equityUnavailable−1.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-5.75 %+29.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+10.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Sector context

Sector call context

Shared sector pressures matched to this company’s latest reporting period.

Similar pressures reported by peers

Tailwind coverage is not available yet.

Similar commentary provides sector context; it does not establish a business relationship with SYMBIOTEC. Each comparison matches a headwind disclosed by SYMBIOTEC in the same calendar reporting quarter.

  • API work is done, but formulation development and FDA approval are out of the company's control

    Topic: Regulatory compliance · Regulatory policy · Q1 FY27

    SYMBIOTEC reported: API work is done, but formulation development and FDA approval are out of the company's control; no timeline given

    Reporting period ended 2026-06-30

    25 other companies · Regulatory policy

    Cipla Limited (CIPLA) reported (period ended 2026-06-30): Timing for Lanreotide regulatory approvals and site transfer is fluid and not included in Q4 projections.

    Glenmark Pharmaceuticals Limited (GLENMARK) reported (period ended 2026-06-30): General regulatory risks in the pharma industry, mitigated by the strategic shift towards an innovative and branded portfolio.

    Anthem Biosciences Limited (ANTHEM) reported (period ended 2026-06-30): Commercial supply of Semaglutide API is awaiting CDSCO approval, which is critical for market entry and sales.

    Narayana Hrudayalaya Ltd. (NH) reported (period ended 2026-06-30): The classification of UK medical software as a medical device requires certification, which has extended regulatory approval timelines by 4-6 months beyond initial anticipation, delaying integration benefits.

    Evidence drawer

    Evidence type: Summary paraphrase

    API work is done, but formulation development and FDA approval are out of the company's control; no timeline given

    Source company: SYMBIOTEC · Reporting period ended 2026-06-30 · Calendar quarter: Q1 FY27 · Distinct companies matched: 25

    Similar commentary provides sector context; it does not establish a business relationship.

  • The company is not backward-integrated into solvents

    Topic: Supply chain disruption · Logistics supply chain · Q1 FY27

    SYMBIOTEC reported: The company is not backward-integrated into solvents; margins could move 'some points' year to year; guidance carries a ±5% band

    Reporting period ended 2026-06-30

    11 other companies · Logistics supply chain

    Glenmark Pharmaceuticals Limited (GLENMARK) reported (period ended 2026-06-30): Increased API and logistics costs due to geopolitical situation impacting gross margins, expected to persist for at least two more quarters.

    GlaxoSmithKline Pharmaceuticals Limited (GLAXO) reported (period ended 2026-06-30): Favorable base effect from last year's CMO disruptions, but the worst is behind and supply chain strengthened.

    Caplin Point Laboratories Limited (CAPLIPOINT) reported (period ended 2026-06-30): Company consciously increased warehouse stock by INR 76 crores and RM/PM inventory by INR 15 crores to shield against potential disruptions and price increases, impacting current CFO.

    Poly Medicure Limited (POLYMED) reported (period ended 2026-06-30): 32% de-growth in Middle East due to ongoing West Asia crisis, logistics, and infrastructure bottlenecks; demand intact but unable to ship products due to disrupted shipping schedules and lack of containers.

    Evidence drawer

    Evidence type: Summary paraphrase

    The company is not backward-integrated into solvents; margins could move 'some points' year to year; guidance carries a ±5% band

    Source company: SYMBIOTEC · Reporting period ended 2026-06-30 · Calendar quarter: Q1 FY27 · Distinct companies matched: 11

    Similar commentary provides sector context; it does not establish a business relationship.

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Live Summary

SYMBIOTEC ₹1,271.5 +3.11%
AI Call Brief · Q1 FY27

SYMBIOTEC Q1 FY27

Overview

Symbol
NSE:SYMBIOTEC
Exchange
NSE
Currency
INR

How the price took the results

Moved an average of ±3.0% across the last 1 priced result release

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q1 FY2722 Sept 267 14−96.6%₹1,156.05 → ₹1,120.9−3.0%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case for SYMBIOTEC

Free account: one company. Everything above stays public.

Write why you follow SYMBIOTEC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on SYMBIOTEC

Compiled directly from SYMBIOTEC's filed financial statements, earnings call transcripts, and ownership disclosures.

How did SYMBIOTEC (SYMBIOTEC) perform in its latest reported quarter (Jun 2026)?

For the quarter ended Jun 2026, SYMBIOTEC reported revenue of ₹7 Cr, net profit of ₹14 Cr, an operating margin of 21.0%. Diluted earnings per share stood at ₹2.24.

How is SYMBIOTEC (SYMBIOTEC) valued today, and what growth does the stock price imply?

SYMBIOTEC (SYMBIOTEC) trades at ₹1,271.5, with a market capitalization of ₹8.2k Cr.

Who owns SYMBIOTEC (SYMBIOTEC) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 33.3%, FIIs hold 3.8%, DIIs hold 33.2%, Public shareholders hold 29.8%.

Learn to analyse SYMBIOTEC

Guides on how to read this kind of business and the numbers that matter.